Targeted protein degradation, TPD, is a new and disruptive therapeutic approach for development of medicines. TPD opened doors to develop small molecules to drug the ‘undruggable’.  Instead of blocking the function of a protein, small molecules can lead to the degradation of the disease causing protein. Small molecules that have these properties are called proteolysis targeting chimeras, PROTACs. In this episode with Alessio Ciulli, we take a deep dive into the transformative potential PROTACs.

Alessio co-founded the biotech company Amphista Therapeutics. The company is focused on developing therapeutics leading targeted protein degradation.